{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:44:44Z","timestamp":1792439084147,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The pandemic of coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a significant impact on the economy and public health worldwide. Therapeutic options such as drugs and vaccines for this newly emerged disease are eagerly desired due to the high mortality. Using the U.S. Food and Drug Administration (FDA) approved drugs to treat a new disease or entirely different diseases, in terms of drug repurposing, minimizes the time and cost of drug development compared to the de novo design of a new drug. Drug repurposing also has some other advantages such as reducing safety evaluation to accelerate drug application on time. Carvedilol, a non-selective beta-adrenergic blocker originally designed to treat high blood pressure and manage heart disease, has been shown to impact SARS-CoV-2 infection in clinical observation and basic studies. Here, we applied computer-aided approaches to investigate the possibility of repurposing carvedilol to combat SARS-CoV-2 infection. The molecular mechanisms and potential molecular targets of carvedilol were identified by evaluating the interactions of carvedilol with viral proteins. Additionally, the binding affinities of in vivo metabolites of carvedilol with selected targets were evaluated. The docking scores for carvedilol and its metabolites with RdRp were \u2212\u200910.0\u00a0kcal\/mol, \u2212\u20099.8\u00a0kcal\/mol (1-hydroxyl carvedilol), \u2212\u20099.7\u00a0kcal\/mol (3-hydroxyl carvedilol), \u2212\u20099.8\u00a0kcal\/mol (4-hydroxyl carvedilol), \u2212\u20099.7\u00a0kcal\/mol (5-hydroxyl carvedilol), \u2212\u200910.0\u00a0kcal\/mol (8-hydroxyl carvedilol), and \u2212\u200910.1\u00a0kcal\/mol (O-desmethyl carvedilol), respectively. Using the molecular dynamics simulation (100\u00a0ns) method, we further confirmed the stability of formed complexes of RNA-dependent RNA polymerase (RdRp) and carvedilol or its metabolites. Finally, the drug-target interaction mechanisms that contribute to the complex were investigated. Overall, this study provides the molecular targets and mechanisms of carvedilol and its metabolites as repurposed drugs to fight against SARS-CoV-2 infection.<\/jats:p>","DOI":"10.1038\/s41598-023-48398-6","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T17:02:42Z","timestamp":1701709362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches"],"prefix":"10.1038","volume":"13","author":[{"given":"Chunye","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"48398_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jmv.25689","volume":"92","author":"W Wang","year":"2020","unstructured":"Wang, W., Tang, J. & Wei, F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J. Med. Virol. 92, 441\u2013447. https:\/\/doi.org\/10.1002\/jmv.25689 (2020).","journal-title":"J. Med. Virol."},{"key":"48398_CR2","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1016\/j.jmb.2020.04.009","volume":"432","author":"JA Jaimes","year":"2020","unstructured":"Jaimes, J. A., Andr\u00e9, N. M., Chappie, J. S., Millet, J. K. & Whittaker, G. R. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop. J. Mol. Biol. 432, 3309\u20133325. https:\/\/doi.org\/10.1016\/j.jmb.2020.04.009 (2020).","journal-title":"J. Mol. Biol."},{"key":"48398_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu, A. et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27, 325\u2013328. https:\/\/doi.org\/10.1016\/j.chom.2020.02.001 (2020).","journal-title":"Cell Host Microbe"},{"key":"48398_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017 (2020).","journal-title":"N. Engl. J. Med."},{"key":"48398_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect 9, 221\u2013236. https:\/\/doi.org\/10.1080\/22221751.2020.1719902 (2020).","journal-title":"Emerg. Microbes Infect"},{"key":"48398_CR6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448. https:\/\/doi.org\/10.1126\/science.abb2762 (2020).","journal-title":"Science"},{"key":"48398_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040821","author":"R Yadav","year":"2021","unstructured":"Yadav, R. et al. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells https:\/\/doi.org\/10.3390\/cells10040821 (2021).","journal-title":"Cells"},{"key":"48398_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116083","author":"C Zhang","year":"2022","unstructured":"Zhang, C. & Yang, M. Newly emerged antiviral strategies for SARS-CoV-2: From deciphering viral protein structural function to the development of vaccines, antibodies, and small molecules. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23116083 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"48398_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00127-20","author":"Y Wan","year":"2020","unstructured":"Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00127-20 (2020).","journal-title":"J. Virol."},{"key":"48398_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/v13010109","author":"X Xia","year":"2021","unstructured":"Xia, X. Domains and functions of spike protein in Sars-Cov-2 in the context of vaccine design. Viruses https:\/\/doi.org\/10.3390\/v13010109 (2021).","journal-title":"Viruses"},{"key":"48398_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"F Li","year":"2016","unstructured":"Li, F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237\u2013261. https:\/\/doi.org\/10.1146\/annurev-virology-110615-042301 (2016).","journal-title":"Annu. Rev. Virol."},{"key":"48398_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/b978-0-12-385885-6.00009-2","volume":"81","author":"SR Weiss","year":"2011","unstructured":"Weiss, S. R. & Leibowitz, J. L. Coronavirus pathogenesis. Adv. Virus Res. 81, 85\u2013164. https:\/\/doi.org\/10.1016\/b978-0-12-385885-6.00009-2 (2011).","journal-title":"Adv. Virus Res."},{"key":"48398_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijbiomac.2021.02.071","volume":"177","author":"A Shamsi","year":"2021","unstructured":"Shamsi, A. et al. Potential drug targets of SARS-CoV-2: From genomics to therapeutics. Int. J. Biol. Macromol. 177, 1\u20139. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.02.071 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"48398_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s41564-021-00954-4","volume":"6","author":"J Zahradn\u00edk","year":"2021","unstructured":"Zahradn\u00edk, J. et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat. Microbiol. 6, 1188\u20131198. https:\/\/doi.org\/10.1038\/s41564-021-00954-4 (2021).","journal-title":"Nat. Microbiol."},{"key":"48398_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","volume":"7","author":"W Yan","year":"2022","unstructured":"Yan, W., Zheng, Y., Zeng, X., He, B. & Cheng, W. Structural biology of SARS-CoV-2: Open the door for novel therapies. Signal Transduct. Target Ther. 7, 26. https:\/\/doi.org\/10.1038\/s41392-022-00884-5 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"48398_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe0751","author":"MD Sacco","year":"2020","unstructured":"Sacco, M. D. et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abe0751 (2020).","journal-title":"Sci. Adv."},{"key":"48398_CR17","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1080\/07391102.2021.1875886","volume":"40","author":"A Mishra","year":"2022","unstructured":"Mishra, A. & Rathore, A. S. RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2. J. Biomol. Struct. Dyn. 40, 6039\u20136051. https:\/\/doi.org\/10.1080\/07391102.2021.1875886 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"48398_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","volume":"96","author":"EJ Snijder","year":"2016","unstructured":"Snijder, E. J., Decroly, E. & Ziebuhr, J. The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv. Virus Res. 96, 59\u2013126. https:\/\/doi.org\/10.1016\/bs.aivir.2016.08.008 (2016).","journal-title":"Adv. Virus Res."},{"key":"48398_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305\u2013315. https:\/\/doi.org\/10.1056\/NEJMoa2116846 (2022).","journal-title":"N. Engl. J. Med."},{"key":"48398_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30, 269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0 (2020).","journal-title":"Cell Res"},{"key":"48398_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662. https:\/\/doi.org\/10.1038\/s41586-020-2601-5 (2020).","journal-title":"Nature"},{"key":"48398_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01969-20","author":"YMO Alhammad","year":"2021","unstructured":"Alhammad, Y. M. O. et al. The SARS-CoV-2 conserved macrodomain Is a mono-ADP-ribosylhydrolase. J. Virol. https:\/\/doi.org\/10.1128\/jvi.01969-20 (2021).","journal-title":"J. Virol."},{"key":"48398_CR23","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1038\/s41467-021-25166-6","volume":"12","author":"JA Newman","year":"2021","unstructured":"Newman, J. A. et al. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase. Nat. Commun. 12, 4848. https:\/\/doi.org\/10.1038\/s41467-021-25166-6 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"48398_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imj.2021.12.004","volume":"1","author":"H Zeng","year":"2022","unstructured":"Zeng, H. et al. SARS-CoV-2 helicase NSP13 hijacks the host protein EWSR1 to promote viral replication by enhancing RNA unwinding activity. Infect. Med. 1(1), 7\u201316. https:\/\/doi.org\/10.1016\/j.imj.2021.12.004 (2022).","journal-title":"Infect. Med."},{"key":"48398_CR25","doi-asserted-by":"publisher","first-page":"e2204539119","DOI":"10.1073\/pnas.2204539119","volume":"119","author":"Z Xu","year":"2022","unstructured":"Xu, Z. et al. SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation. Proc. Natl. Acad. Sci. U S A 119, e2204539119. https:\/\/doi.org\/10.1073\/pnas.2204539119 (2022).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"48398_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","volume":"23","author":"B Malone","year":"2022","unstructured":"Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 23, 21\u201339. https:\/\/doi.org\/10.1038\/s41580-021-00432-z (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"48398_CR27","doi-asserted-by":"publisher","first-page":"105575","DOI":"10.1016\/j.compbiomed.2022.105575","volume":"146","author":"N Eskandarzade","year":"2022","unstructured":"Eskandarzade, N. et al. Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs. Comput. Biol. Med. 146, 105575. https:\/\/doi.org\/10.1016\/j.compbiomed.2022.105575 (2022).","journal-title":"Comput. Biol. Med."},{"key":"48398_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erc.11.166","volume":"10","author":"JJ DiNicolantonio","year":"2012","unstructured":"DiNicolantonio, J. J. & Hackam, D. G. Carvedilol: A third-generation \u03b2-blocker should be a first-choice \u03b2-blocker. Expert Rev. Cardiovasc. Ther. 10, 13\u201325. https:\/\/doi.org\/10.1586\/erc.11.166 (2012).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"48398_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00005344-200405000-00002","volume":"43","author":"O Saijonmaa","year":"2004","unstructured":"Saijonmaa, O., Nyman, T. & Fyhrquist, F. Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. J. Cardiovasc. Pharmacol. 43, 616\u2013621. https:\/\/doi.org\/10.1097\/00005344-200405000-00002 (2004).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"48398_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01474-0","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-022-01474-0 (2022).","journal-title":"Nat. Biotechnol."},{"key":"48398_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/0953710021000057848","volume":"13","author":"M Petr\u00edkov\u00e1","year":"2002","unstructured":"Petr\u00edkov\u00e1, M., Jancinov\u00e1, V., Nos\u00e1l, R., M\u00e1jekov\u00e1, M. & Danihelov\u00e1, E. Antiplatelet activity of carvedilol in comparison to propranolol. Platelets 13, 479\u2013485. https:\/\/doi.org\/10.1080\/0953710021000057848 (2002).","journal-title":"Platelets"},{"key":"48398_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood.2020007805","volume":"136","author":"EM Battinelli","year":"2020","unstructured":"Battinelli, E. M. COVID-19 concerns aggregate around platelets. Blood 136, 1221\u20131223. https:\/\/doi.org\/10.1182\/blood.2020007805 (2020).","journal-title":"Blood"},{"key":"48398_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.amjms.2020.05.030","volume":"360","author":"C Skayem","year":"2020","unstructured":"Skayem, C. & Ayoub, N. Carvedilol and COVID-19: A potential role in reducing infectivity and infection severity of SARS-CoV-2. Am. J. Med. Sci. 360, 300. https:\/\/doi.org\/10.1016\/j.amjms.2020.05.030 (2020).","journal-title":"Am. J. Med. Sci."},{"key":"48398_CR34","first-page":"253","volume":"39","author":"T Matsumura","year":"2002","unstructured":"Matsumura, T. et al. Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J. Cardiol. 39, 253\u2013257 (2002).","journal-title":"J. Cardiol."},{"key":"48398_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/ejhpharm-2020-002322","volume":"27","author":"T Palanques-Pastor","year":"2020","unstructured":"Palanques-Pastor, T., L\u00f3pez-Briz, E. & Poveda Andr\u00e9s, J. L. Involvement of interleukin 6 in SARS-CoV-2 infection: Siltuximab as a therapeutic option against COVID-19. Eur. J. Hosp. Pharm. 27, 297\u2013298. https:\/\/doi.org\/10.1136\/ejhpharm-2020-002322 (2020).","journal-title":"Eur. J. Hosp. Pharm."},{"key":"48398_CR36","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.4251\/wjgo.v14.i8.1456","volume":"14","author":"CY Zhang","year":"2022","unstructured":"Zhang, C. Y., Liu, S. & Yang, M. Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression. World J. Gastrointest. Oncol. 14, 1456\u20131468. https:\/\/doi.org\/10.4251\/wjgo.v14.i8.1456 (2022).","journal-title":"World J. Gastrointest. Oncol."},{"key":"48398_CR37","first-page":"970","volume":"25","author":"HG Oldham","year":"1997","unstructured":"Oldham, H. G. & Clarke, S. E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 25, 970\u2013977 (1997).","journal-title":"Drug Metab. Dispos."},{"key":"48398_CR38","doi-asserted-by":"publisher","first-page":"1934578x2211154","DOI":"10.1177\/1934578x221115499","volume":"17","author":"S Ahmad","year":"2022","unstructured":"Ahmad, S. et al. Multitargeted molecular dynamic understanding of butoxypheser against SARS-CoV-2: An in silico study. Nat. Prod. Commun. 17, 1934578x221115499. https:\/\/doi.org\/10.1177\/1934578x221115499 (2022).","journal-title":"Nat. Prod. Commun."},{"key":"48398_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"48398_CR40","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1080\/07391102.2021.2021993","volume":"41","author":"MK Yadav","year":"2023","unstructured":"Yadav, M. K. et al. Predictive modeling and therapeutic repurposing of natural compounds against the receptor-binding domain of SARS-CoV-2. J. Biomol. Struct. Dyn. 41, 1527\u20131539. https:\/\/doi.org\/10.1080\/07391102.2021.2021993 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"48398_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184331","author":"L Pinzi","year":"2019","unstructured":"Pinzi, L. & Rastelli, G. Molecular docking: Shifting paradigms in drug discovery. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20184331 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"48398_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drudis.2021.09.007","volume":"27","author":"K Crampon","year":"2022","unstructured":"Crampon, K., Giorkallos, A., Deldossi, M., Baud, S. & Steffenel, L. A. Machine-learning methods for ligand-protein molecular docking. Drug Discov. Today 27, 151\u2013164. https:\/\/doi.org\/10.1016\/j.drudis.2021.09.007 (2022).","journal-title":"Drug Discov. Today"},{"key":"48398_CR43","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.drudis.2022.03.006","volume":"27","author":"C Choudhury","year":"2022","unstructured":"Choudhury, C., Arul Murugan, N. & Priyakumar, U. D. Structure-based drug repurposing: Traditional and advanced AI\/ML-aided methods. Drug Discov. Today 27, 1847\u20131861. https:\/\/doi.org\/10.1016\/j.drudis.2022.03.006 (2022).","journal-title":"Drug Discov. Today"},{"key":"48398_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/bs.pmch.2021.01.004","volume":"60","author":"F Stanzione","year":"2021","unstructured":"Stanzione, F., Giangreco, I. & Cole, J. C. Use of molecular docking computational tools in drug discovery. Prog. Med. Chem. 60, 273\u2013343. https:\/\/doi.org\/10.1016\/bs.pmch.2021.01.004 (2021).","journal-title":"Prog. Med. Chem."},{"key":"48398_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"XY Meng","year":"2011","unstructured":"Meng, X. Y., Zhang, H. X., Mezei, M. & Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug. Des. 7, 146\u2013157. https:\/\/doi.org\/10.2174\/157340911795677602 (2011).","journal-title":"Curr. Comput. Aided Drug. Des."},{"key":"48398_CR46","first-page":"845","volume":"83","author":"B McConkey","year":"2002","unstructured":"McConkey, B., Sobolev, V. & Edelman, M. The performance of current methods in ligand-protein docking. Curr. Sci. 83, 845 (2002).","journal-title":"Curr. Sci."},{"key":"48398_CR47","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685. https:\/\/doi.org\/10.1038\/s41586-023-05905-z (2023).","journal-title":"Nature"},{"key":"48398_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/aabc.S105289","volume":"9","author":"J de Ruyck","year":"2016","unstructured":"de Ruyck, J., Brysbaert, G., Blossey, R. & Lensink, M. F. Molecular docking as a popular tool in drug design, an in silico travel. Adv. Appl. Bioinform. Chem. 9, 1\u201311. https:\/\/doi.org\/10.2147\/aabc.S105289 (2016).","journal-title":"Adv. Appl. Bioinform. Chem."},{"key":"48398_CR49","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/ph16101479","volume":"16","author":"C Zhang","year":"2023","unstructured":"Zhang, C., Sui, Y., Liu, S. & Yang, M. Anti-viral activity of bioactive molecules of silymarin against COVID-19 via in silico studies. Pharmaceuticals 16, 1479 (2023).","journal-title":"Pharmaceuticals"},{"key":"48398_CR50","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.crbiot.2023.100121","volume":"5","author":"M Yang","year":"2023","unstructured":"Yang, M., Liu, S. & Zhang, C. Antimicrobial peptides with antiviral and anticancer properties and their modification and nanodelivery systems. Curr. Res. Biotechnol. 5, 100121. https:\/\/doi.org\/10.1016\/j.crbiot.2023.100121 (2023).","journal-title":"Curr. Res. Biotechnol."},{"key":"48398_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2174\/1389450119666181022153016","volume":"20","author":"S Saikia","year":"2019","unstructured":"Saikia, S. & Bordoloi, M. Molecular docking: Challenges, advances and its use in drug discovery perspective. Curr. Drug Targets 20, 501\u2013521. https:\/\/doi.org\/10.2174\/1389450119666181022153016 (2019).","journal-title":"Curr. Drug Targets"},{"key":"48398_CR52","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1074\/jbc.R115.668251","volume":"290","author":"A Jazayeri","year":"2015","unstructured":"Jazayeri, A., Dias, J. M. & Marshall, F. H. From G protein-coupled receptor structure resolution to rational drug design. J. Biol. Chem. 290, 19489\u201319495. https:\/\/doi.org\/10.1074\/jbc.R115.668251 (2015).","journal-title":"J. Biol. Chem."},{"key":"48398_CR53","doi-asserted-by":"publisher","first-page":"17716","DOI":"10.1038\/s41598-020-74468-0","volume":"10","author":"S Keretsu","year":"2020","unstructured":"Keretsu, S., Bhujbal, S. P. & Cho, S. J. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. Sci. Rep. 10, 17716. https:\/\/doi.org\/10.1038\/s41598-020-74468-0 (2020).","journal-title":"Sci. Rep."},{"key":"48398_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/pr9010071","volume":"9","author":"OMH Salo-Ahen","year":"2021","unstructured":"Salo-Ahen, O. M. H. et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9, 71 (2021).","journal-title":"Processes"},{"key":"48398_CR55","doi-asserted-by":"publisher","first-page":"3502514","DOI":"10.1155\/2018\/3502514","volume":"2018","author":"Y Fu","year":"2018","unstructured":"Fu, Y., Zhao, J. & Chen, Z. Insights into the molecular mechanisms of protein-ligand interactions by molecular docking and molecular dynamics simulation: A case of oligopeptide binding protein. Comput. Math. Methods Med. 2018, 3502514. https:\/\/doi.org\/10.1155\/2018\/3502514 (2018).","journal-title":"Comput. Math. Methods Med."},{"key":"48398_CR56","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1007\/s11224-020-01605-w","volume":"31","author":"R Jain","year":"2020","unstructured":"Jain, R. & Mujwar, S. Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19. Struct. Chem. 31, 2487\u20132499. https:\/\/doi.org\/10.1007\/s11224-020-01605-w (2020).","journal-title":"Struct. Chem."},{"key":"48398_CR57","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s11224-022-01943-x","volume":"33","author":"S Mujwar","year":"2022","unstructured":"Mujwar, S. & Harwansh, R. K. In silico bioprospecting of taraxerol as a main protease inhibitor of SARS-CoV-2 to develop therapy against COVID-19. Struct. Chem. 33, 1517\u20131528. https:\/\/doi.org\/10.1007\/s11224-022-01943-x (2022).","journal-title":"Struct. Chem."},{"key":"48398_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27238287","author":"M Kciuk","year":"2022","unstructured":"Kciuk, M. et al. Computational bioprospecting guggulsterone against ADP ribose phosphatase of SARS-CoV-2. Molecules https:\/\/doi.org\/10.3390\/molecules27238287 (2022).","journal-title":"Molecules"},{"key":"48398_CR59","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11030-022-10440-6","volume":"27","author":"O Fidan","year":"2023","unstructured":"Fidan, O., Mujwar, S. & Kciuk, M. Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing. Mol. Divers 27, 463\u2013475. https:\/\/doi.org\/10.1007\/s11030-022-10440-6 (2023).","journal-title":"Mol. Divers"},{"key":"48398_CR60","doi-asserted-by":"publisher","first-page":"104748","DOI":"10.1016\/j.compbiomed.2021.104748","volume":"136","author":"S Mujwar","year":"2021","unstructured":"Mujwar, S. Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2. Comput. Biol. Med. 136, 104748. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104748 (2021).","journal-title":"Comput. Biol. Med."},{"key":"48398_CR61","doi-asserted-by":"publisher","first-page":"19125","DOI":"10.1038\/s41598-020-75762-7","volume":"10","author":"NA Murugan","year":"2020","unstructured":"Murugan, N. A., Kumar, S., Jeyakanthan, J. & Srivastava, V. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach. Sci. Rep. 10, 19125. https:\/\/doi.org\/10.1038\/s41598-020-75762-7 (2020).","journal-title":"Sci. Rep."},{"key":"48398_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2141","volume":"30","author":"EA Coomes","year":"2020","unstructured":"Coomes, E. A. & Haghbayan, H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev. Med. Virol. 30, 1\u20139. https:\/\/doi.org\/10.1002\/rmv.2141 (2020).","journal-title":"Rev. Med. Virol."},{"key":"48398_CR63","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/1744666x.2021.1919086","volume":"17","author":"N Potere","year":"2021","unstructured":"Potere, N. et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev. Clin. Immunol. 17, 601\u2013618. https:\/\/doi.org\/10.1080\/1744666x.2021.1919086 (2021).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"48398_CR64","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1161\/hypertensionaha.123.21174","volume":"80","author":"V Zhang","year":"2023","unstructured":"Zhang, V., Fisher, M., Hou, W., Zhang, L. & Duong, T. Q. Incidence of new-onset hypertension post-COVID-19: Comparison with influenza. Hypertension 80, 2135\u20132148. https:\/\/doi.org\/10.1161\/hypertensionaha.123.21174 (2023).","journal-title":"Hypertension"},{"key":"48398_CR65","doi-asserted-by":"crossref","unstructured":"Tripathi, M. K., Ahmad, S., Tyagi, R., Dahiya, V. & Yadav, M. K. in Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches (eds Mithun Rudrapal & Chukwuebuka Egbuna) 125\u2013155 (Elsevier, 2022).","DOI":"10.1016\/B978-0-323-90608-1.00001-0"},{"key":"48398_CR66","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"48398_CR67","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. F. & Forli, S. AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. J. Chem. Inf. Model 61, 3891\u20133898. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203 (2021).","journal-title":"J. Chem. Inf. Model"},{"key":"48398_CR68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41401-019-0228-6","volume":"41","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. CB-Dock: A web server for cavity detection-guided protein-ligand blind docking. Acta Pharmacol. Sin. 41, 138\u2013144. https:\/\/doi.org\/10.1038\/s41401-019-0228-6 (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"48398_CR69","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1021\/ci100241y","volume":"50","author":"A Volkamer","year":"2010","unstructured":"Volkamer, A., Griewel, A., Grombacher, T. & Rarey, M. Analyzing the topology of active sites: On the prediction of pockets and subpockets. J. Chem. Inf. Model 50, 2041\u20132052. https:\/\/doi.org\/10.1021\/ci100241y (2010).","journal-title":"J. Chem. Inf. Model"},{"key":"48398_CR70","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1021\/ci200454v","volume":"52","author":"A Volkamer","year":"2012","unstructured":"Volkamer, A., Kuhn, D., Grombacher, T., Rippmann, F. & Rarey, M. Combining global and local measures for structure-based druggability predictions. J. Chem. Inf. Model 52, 360\u2013372. https:\/\/doi.org\/10.1021\/ci200454v (2012).","journal-title":"J. Chem. Inf. Model"},{"key":"48398_CR71","doi-asserted-by":"publisher","first-page":"W48","DOI":"10.1093\/nar\/gkaa235","volume":"48","author":"K Sch\u00f6ning-Stierand","year":"2020","unstructured":"Sch\u00f6ning-Stierand, K. et al. ProteinsPlus: Interactive analysis of protein-ligand binding interfaces. Nucleic Acids Res. 48, W48-w53. https:\/\/doi.org\/10.1093\/nar\/gkaa235 (2020).","journal-title":"Nucleic Acids Res."},{"key":"48398_CR72","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model 51, 2778\u20132786. https:\/\/doi.org\/10.1021\/ci200227u (2011).","journal-title":"J. Chem. Inf. Model"},{"key":"48398_CR73","unstructured":"Bowers, K. J. et al. in SC '06: Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing. 43\u201343."},{"key":"48398_CR74","unstructured":"Desmond Molecular Dynamics System, D. E. Shaw Research. Maestro-Desmond Interoperability Tools, Schr\u00f6dingerSchr\u00f6dinger, New York, NY."},{"key":"48398_CR75","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717. https:\/\/doi.org\/10.1038\/srep42717 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48398-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48398-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48398-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T17:09:18Z","timestamp":1701709758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48398-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["48398"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48398-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21404"}}